Zydus secures licensing rights for next-gen immuno-oncology platforms from US-based Agenus
Zydus Lifesciences Limited, including its subsidiaries and affiliates ('Zydus'), has entered into an agreement with Agenus Inc. (NASDAQ: AGEN) to acquire the commercial rights for its investigational Botensilimab (BOT) and Balstilimab (BAL), combination therapy.
Agenus is a clinical-stage immuno-oncology company focused on developing immune therapies for cancer treatment. The BOT/BAL combination is an immunotherapy currently in advanced clinical trials. It has shown clinical activity in studies involving over 1,200 patients with nine different types of cancer, in both late-stage and neoadjuvant treatment settings.
Under the agreement, Zydus will handle clinical development and regulatory approvals for BOT/BAL in India and Sri Lanka. Upon successful approval and commercialization, Zydus will pay Agenus a 5% royalty on net sales.
Zydus will also work on expanding the use of BOT/BAL beyond its initial indications to other areas with unmet medical needs and earlier treatment stages, including neoadjuvant therapy.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
19 minutes ago
- Business Insider
Jefferies Bangs the Drum on Nvidia Stock
Nvidia (NASDAQ:NVDA) shares are back in rally mode. Since hitting a low in early April, following market turmoil sparked by Trump's sweeping tariff plans, the stock has soared 50%. The momentum was fueled by a strong Q1 report that confirmed Nvidia's ability to deliver, even with the China chip ban in effect. Confident Investing Starts Here: Wall Street is taking notice. Jefferies' Blayne Curtis, one of the top 1% of analysts on the Street, just added Nvidia to his elite list of Franchise Picks, signaling renewed conviction in the chipmaker's long-term upside. What's behind its inclusion? The 5-star analyst explained: 'We view NVDA as the dominant supplier of AI accelerators within the data center, an industry that is expanding rapidly due to the development and adoption of AI. The ramp of the co's next-generation Blackwell GPU platform is now fully underway, so GM should improve from the low-70% to mid-70% range throughout the year.' Moreover, sovereign AI is seeing a significant boost, with recent commitments from Saudi Arabia and the UAE to develop their AI infrastructure in partnership with Nvidia. What Curtis thinks the market seems to be overlooking is that Nvidia's revenue guide – roughly in line with Street expectations for next quarter – is actually a 'major positive.' The company managed to absorb around $8 billion in revenue headwinds from the H20 export restrictions to China, which was notably higher than the $5 to $6 billion the Street had anticipated. Looking ahead to the second half of the year, Curtis sees a 'favorable setup' as Blackwell Ultra ramps up and the company continues to see solid momentum in networking (NVLink and Spectrum-X). Curtis also expects a more seamless transition to Nvidia's next-generation Rubin platform, thanks to its architectural similarity to Blackwell. Potential catalysts to look forward to include stronger-than-expected demand for Blackwell, mainly fueled by rising CSP (cloud service provider) spending; further sovereign AI investments; the unveiling of a data center product tailored for China; and increased capital expenditures from hyperscalers. Bottom line, Curtis is backing Nvidia with conviction, assigning a Buy rating and a $185 price target – implying a 31% upside from current levels. (To watch Curtis's track record, click here) That's a pretty common take on Wall Street; based on a mix of 35 Buys, 4 Holds and 1 Sell, NVDA stock claims a Strong Buy consensus rating. Going by the $173.57 average price target, a year from now, shares will deliver returns of ~22%. (See ) To find good ideas for AI stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Business Insider
19 minutes ago
- Business Insider
Dollar Tree (DLTR) Gets a Hold from Gordon Haskett Capital Corporation
Gordon Haskett Capital Corporation analyst Charles Grom maintained a Hold rating on Dollar Tree (DLTR – Research Report) today and set a price target of $90.00. The company's shares closed today at $88.62. Confident Investing Starts Here: Grom covers the Consumer Cyclical sector, focusing on stocks such as Dollar General, Home Depot, and Dollar Tree. According to TipRanks, Grom has an average return of 9.7% and a 58.78% success rate on recommended stocks. In addition to Gordon Haskett Capital Corporation, Dollar Tree also received a Hold from Telsey Advisory's Jason Strominger in a report issued today. However, on the same day, Truist Financial maintained a Buy rating on Dollar Tree (NASDAQ: DLTR). The company has a one-year high of $121.92 and a one-year low of $60.49. Currently, Dollar Tree has an average volume of 5.3M. Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is neutral on the stock. Most recently, in April 2025, Stewart Glendinning, the CFO of DLTR bought 17,000.00 shares for a total of $1,236,660.00.
Business Upturn
an hour ago
- Business Upturn
Dr. Reddy's shares surge 4% after company partners with Alvotech to develop and commercialize Biosimilar to Keytruda
By Aman Shukla Published on June 5, 2025, 09:29 IST Shares of Dr. Reddy's Laboratories rose 4% in morning trade after the company announced a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilars. The two companies will co-develop and manufacture a biosimilar version of Keytruda® (pembrolizumab), a blockbuster immunotherapy drug used to treat various cancers. Keytruda® generated global sales of US$29.5 billion in 2024, highlighting the significant market potential for its biosimilar version. Through this partnership, Dr. Reddy's and Alvotech aim to accelerate development timelines and expand access to affordable cancer treatments across international markets. As part of the agreement, both firms will jointly invest in R&D, manufacturing, and regulatory processes. Each partner retains global commercialization rights, with certain market exceptions, allowing for broad market reach while optimizing operational efficiency. Dr. Reddy's Laboratories shares opened at ₹1,264.20 and at the time of writing, surged to an intraday high of ₹1,303.40, matching the day's low at the opening price. The stock is trading near its 52-week high of ₹1,421.49, significantly above its 52-week low of ₹1,020.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
